People: Pluristem Therapeutics, Inc. (PSTI.O)
PSTI.O on Consolidated Issue listed on NASDAQ Capital Market
1.16USD
9 Feb 2010
1.16USD
9 Feb 2010
Price Change (% chg)
$-0.01 (-0.85%)
$-0.01 (-0.85%)
Prev Close
$1.16
$1.16
Open
--
--
Day's High
$1.18
$1.18
Day's Low
$1.12
$1.12
Volume
93,199
93,199
Avg. Vol
123,876
123,876
52-wk High
$1.85
$1.85
52-wk Low
$0.82
$0.82
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Aberman, Zami | 55 | 2006 | Chairman of the Board, President, Chief Executive Officer |
| Yanay, Yaky | 38 | 2006 | Chief Financial Officer, Secretary |
| Shorrer, Doron | 56 | 2006 | Director |
| Meretzki, Hava | 40 | 2005 | Director |
| Ben-Yoram, Israel | 48 | 2005 | Director |
| Braun, Issac | 56 | 2005 | Director |
| Germain, Mark | 59 | 2009 | Director |
| Rosman, Nachum | 63 | 2007 | Director |
| Pines, Shai | 55 | 2008 | Director |
Biographies
| Name | Description |
|---|---|
| Aberman, Zami | Mr. Aberman is Chairman of the Board, President, Chief Executive Officer of Pluristem Therapeutics, Inc. He became Company's Chief Executive Officer and President in September 2005 and a Director of the Company in November 2005. Mr. Aberman has served as Company's Chairman of the Board since April 2006, and between May 2007 and February 2009 he was Co-chairman with Mr. Mark Germain. He has 20 years of experience in marketing and management in the hi-tech industry. He held Chief Executive and Chairman positions in companies in Israel, the United States, Europe, Japan and Korea. Mr. Aberman operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotic markets. Mr. Aberman serves as the chairman of Rose Hitech Ltd., a private investment company; as the chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a director of Ori Software Ltd., a private company engaged in data management. Before serving in those positions he served, between 2002 and 2005, as the President and CEO of Elbit Vision Systems, a public company traded on the OTCBB market (EVSNF.OB) which supplies inspection systems for the microelectronic industry. In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel. |
| Yanay, Yaky | Mr. Yaky Yanay is Chief Financial Officer, Secretary of Pluristem Therapeutics, Inc. since November 1, 2006. Prior to joining Pluristem in 2002, Mr. Yanay was the chief financial officer of Elbit Vision System Ltd. (EVSNF.OB), a company engaged in automatic optical inspection. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting from the college of management studies in Rishon Le Zion, Israel and is a certified public accountant in Israel. |
| Shorrer, Doron | Mr. Doron Shorrer is Director of Pluristem Therapeutics, Inc. in October 2003. Between 2002 and 2004 he was chairman of the board of Phoenix Insurance Company, one of the largest insurance companies in Israel, and Mivtachim Pension Benefit Group, the largest pension fund in Israel. Prior to serving in these positions, Mr. Shorrer held senior positions that included Arbitrator at the Claims Resolution Tribunal for Dormant Accounts in Switzerland; Economic and Financial Advisor, Commissioner of Insurance and Capital Markets for the State of Israel; member of the Board of Directors of “Nechasim” of the State of Israel; member of the Committee for the Examination of Structural Changes in the Capital Market (The Brodet Committee); General Director of the Ministry of Transport; Co-Founder and director of an accounting firm with offices in Jerusalem, Tel-Aviv and Haifa; member of the Lecture Staff of the Amal School Chain; Chairman of a Public Committee for Telecommunications; and Economic Consultant to the Ministry of Energy. Among his many areas of expertise, Mr. Shorrer formulates, implements and administers business planning in the private and institutional sector in addition to consulting on economic, accounting and taxation issues to a large audience ranging from private concerns to government ministries. Mr. Shorrer holds a B.A. in economics and accounting and an M.A. in business administration (with a specialization in finance and banking) from the Hebrew University of Jerusalem and is a certified public accountant (ISR). |
| Meretzki, Hava | Ms. Hava Meretzki is Director of Pluristem Therapeutics, Inc. in October 2003. Ms. Meretzki is an attorney and is a partner in the law firm of Ben-Noun Meretzki in Haifa, Israel. Ms. Meretzki specializes in civil, trade and labor law and is presently Vice-Chairman for the National Council of the Israel Bar Association. Ms. Meretzki received a Bachelors Degree in Law from the Hebrew University in 1991, and in 1992 was admitted to the Israel Bar Association in 1993. |
| Ben-Yoram, Israel | Mr. Israel Ben-Yoram is Director of Pluristem Therapeutics, Inc. since January 2005. He has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel since 1985. In addition, since 1992, Mr. Ben-Yoram has been a shareholder and served as the head director of Mor, Ben-Yoram Ltd., a private company in Israel that operates parallel to Mor, Ben-Yoram and Partners, which provides management services, economic consulting services and other professional services to businesses. Mr. Ben-Yoram received a B.A. in accounting from the University of Tel Aviv, an M.A. in economics from the Hebrew University of Jerusalem, an LLB and an MBA from Tel Aviv University and an LLM from Bar Ilan University. |
| Braun, Issac | Mr. Isaac Braun is Director of Pluristem Therapeutics, Inc. since July 2005. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He has been a co-founder and board member of several hi-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun is involved with advising private companies on raising financing and business development. |
| Germain, Mark | Mr. Germain became a Director of the Pluristem Therapeutics, Inc. in May 2007. Between May 2007 and February 2009, Mr. Germain served as Co-Chairman of Company's Board. For more than five years, Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries. He has been involved as a founder, director, Chairman of the Board of, and/or investor in, over twenty companies in the biotech field, and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated from New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law before leaving in 1986. Since then, and until he entered the biotech field in 1991, he served in senior executive capacities, including as president of a public company sold in 1991. In addition to being Co-Chairman of the Company, Mr. Germain is a director of the following publicly traded companies: Stem Cell Innovations, Inc., ChromaDex, Inc., Omnimmune Corp. and Collexis Holdings, Inc. He is also a co-founder and director of a number of private companies in the biotechnology field. |
| Rosman, Nachum | Mr. Nachum Rosman is Director of Pluristem Therapeutics, Inc. in October 2007. In 1999, Mr. Rosman founded Talecity Ltd, a movie production company, and has since been serving as its chief financial officer. In addition he provides management and consulting services to startup companies in the financial, organizational and human resource aspects of their operations. Mr. Rosman also serves as a director at several privately held companies. Throughout his career, Mr. Rosman held chief executive and chief financial officer positions in Israel, the United States and Great Britain. In these positions he was responsible, among other things, for finance management, fund raising, acquisitions and technology sales. Mr. Rosman holds a B.Sc. in management engineering and a M.Sc. in operations research from the Technion in Israel. Mr. Rosman also participated in a Ph.D. program in investments and financing at the Tel Aviv University in Israel. |
| Pines, Shai | Mr. Shai Pines is Director of Pluristem Therapeutics Inc. since December, 2008. He is a lawyer admitted to practice law in the State of Israel since 1981. He is a partner with, and heads the Commercial and International Transactions Department of, the Israeli law firm of Hamburger Evron & Co. Since 2000 Mr. Pines served as a member of the Supervisory Board of Globe Trade Centre SA (GTC), a Polish company, which is traded on the Warsaw Stock Exchange, and between the years 2000 – 2005 as a member of the Supervisory Board of GTC International BV, a Dutch private company. Mr. Pines is also a member of the Board of Governors of the Law Faculty of the Tel-Aviv University since 2006. Mr. Pines holds an MBA degree from Kellogg School of Management, Northwestern University, U.S.A. & the Leon Recanati Graduate School of Business Administration, Tel-Aviv University, and an LL.B. degree from Tel-Aviv University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Aberman, Zami | 580,298 |
| Yanay, Yaky | 319,251 |
| Shorrer, Doron | -- |
| Meretzki, Hava | -- |
| Ben-Yoram, Israel | -- |
| Braun, Issac | -- |
| Germain, Mark | -- |
| Rosman, Nachum | -- |
| Pines, Shai | -- |
As Of 29 Jun 2009
Options Compensation
| Name | Options | Value |
|---|---|---|
| Aberman, Zami | 60,500,000 | 0 |
| Yanay, Yaky | 12,500,000 | 0 |
| Shorrer, Doron | 12,851,170 | 0 |
| Meretzki, Hava | 8,538,377 | 0 |
| Ben-Yoram, Israel | 8,355,089 | 0 |
| Braun, Issac | 8,284,594 | 0 |
| Germain, Mark | 50,000,001 | 0 |
| Rosman, Nachum | 0 | 0 |
| Pines, Shai | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| YANAY YAKY | 70,000 | $0.00 |
| PINES SHAI | 35,000 | $0.00 |
| BRAUN ISAAC | 35,000 | $0.00 |
| MERETZKI HAVA | 35,000 | $0.00 |
| ABERMAN ZAMI | 140,000 | $0.00 |
| ROZMAN NAHUM | 35,000 | $0.00 |
| GERMAIN MARK S | 35,000 | $0.00 |
| SHORRER DOREN | 35,000 | $0.00 |
| BEN YORAM ISRAEL | 35,000 | $0.00 |
| ROZMAN NAHUM | 3,200 | $0.00 |
| MERETZKI HAVA | 3,200 | $0.00 |
| PINES SHAI | 3,200 | $0.00 |
| ABERMAN ZAMI | 38,700 | $0.00 |
| YANAY YAKY | 21,300 | $0.00 |
| SHORRER DOREN | 3,200 | $0.00 |
| BRAUN ISAAC | 3,200 | $0.00 |
| BEN YORAM ISRAEL | 3,200 | $0.00 |
| GERMAIN MARK S | 3,200 | $0.00 |
| YANAY YAKY | 70,000 | $0.00 |
| PINES SHAI | 35,000 | $0.00 |
| BRAUN ISAAC | 35,000 | $0.00 |
| BEN YORAM ISRAEL | 35,000 | $0.00 |
| MERETZKI HAVA | 35,000 | $0.00 |
| ROZMAN NAHUM | 35,000 | $0.00 |
| ABERMAN ZAMI | 140,000 | $0.00 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
